Abstract Library

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4556 Optimising the establishment of patient-derived models for neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are clinically and molecularly diverse, with limited understanding of their tumour biology. Efforts to develop patient-derived models have been unsuccessful, highlighting an urgent need for accurate models to support fundamental research.

Conference:

Presenting Author: Hernández Llorens M

Authors: Hernández-Llorens M, Baena-Moreno M, Lamas-Paz A, Sarmentero J, Anton-Pascual B,

Keywords: patient-derived model, organoids, PDXs, Growth factor,

#4183 Establishment of novel patient-derived preclinical models for neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) arise in different organs and are heterogeneous with limited treatment options. Preclinical models established from patient tumor specimens enable precision oncology by assessing the response to various drug treatments.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Li B, Li Y, Tsui H,

Keywords: preclinical models, patient-derived organoids, patient-derived xenografts, drug screening,

#3955 Development of clinically representative patient-derived organoid models for diverse G1/G2 gastroenteropancreatic neuroendocrine tumors

Introduction: While gastroenteropancreatic neuroendocrine tumors (GEP-NETs) grow slowly, they are incurable when reaching advanced stages. The characteristic slow growth of GEP-NETs results in the scarcity of clinically relevant models that has hindered our comprehension of GEP-NET biology and pathology, leading to limited progress in systemic therapies of GEP-NET treatment.

Conference:

Presenting Author:

Authors: Zuo X, Liu Y, Maxwelll J, Halperin D, Dasari A,

Keywords: gastroenteropancreatic neuroendocrine tumors, patient-derived organoids, Dox-controlled genetic modifications, characterization,

#3931 Construction and comparison of non-functional pancreatic neuroendocrine tumor models

Introduction: Pancreatic neuroendocrine tumors (PNET) which account for more than 80% of pancreatic neuroendocrine neoplasm (pNEN) can be divided into functional and non-functional. The non-functional pancreatic neuroendocrine tumor (NF-pNET) without hormone-related clinical symptoms is frequently found by chance during physical examination or in large primaries and late stages of disease.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Ye Z, Lou X, Xu J, Zhou C,

Keywords: pancreatic neuroendocrine tumor, preclinical model, cell line, patient-derived organoid, patient-derived xenograft,